Exclusive: Deerfield secures $600M+ for third healthcare venture fund to seed new companies

Kyle LaHucik

Senior Reporter

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new drug development outfits, medical technology …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Deerfield secures $600M+ for third healthcare venture fund to seed new companies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

Exclusive: Topas claims success in early test of 'immune tolerance' therapy for celiac disease

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Ex­clu­sive: Deer­field se­cures $600M+ for third health­care ven­ture fund to seed new com­pa­nies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Ex­clu­sive: Topas claims suc­cess in ear­ly test of 'im­mune tol­er­ance' ther­a­py for celi­ac dis­ease

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Exclusive: Deerfield secures $600M+ for third healthcare venture fund to seed new companies

Early bits of in vivo CAR-T human data emerge from biotech trials in China

Recursion cuts nearly half of its pipeline, including its most advanced program

Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership

Exclusive: Topas claims success in early test of 'immune tolerance' therapy for celiac disease

J&J's eye disease gene therapy bota-vec fails in Phase 3 trial

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges